Organigram Global (NASDAQ:OGI) reported a dominant start to its fiscal 2026 on Tuesday, posting a 49% year-over-year surge in net revenue to $63.5 million.
The results, released February 10, 2026, mark the first quarterly report under new CEO James Yamanaka, who recently succeeded long-time chief Beena Goldenberg.
Yamanaka, who spent his first 25 days touring the company's Moncton and Lac-Supérieur facilities, emphasized a future focused on "efficiency and scale" as Organigram cements its position as Canada's top cannabis company by market share.
The company's bottom line saw even more dramatic improvement, with adjusted EBITDA skyrocketing 273% to $5.3 million.
This profitability was supported by a 43% increase in total kilograms harvested (28,645 kg), achieved through nutrient enhancements that lowered per-unit production costs.
Organigram maintained its #1 rank in the Canadian vape, milled flower, and concentrate categories, while its international revenue grew 51% to $5 million, fueled by exports to Israel, Australia, and Germany.
Beyond the financials, Organigram announced a proprietary genetic screening breakthrough that could revolutionize cultivation efficiency.
The company’s new molecular tool can identify powdery mildew resistance in cultivars in just days rather than months.
By breeding this resistance into its commercial lines, Organigram expects to significantly reduce crop loss and eliminate the need for costly chemical interventions, further boosting its margin profile.
The quarter also highlighted Organigram’s aggressive U.S. strategy following its acquisition of Collective Project.
The company has now expanded its hemp-derived THC beverage footprint to 11 states, including recent launches in Illinois and Wisconsin.
Backed by a $124.6 million investment from British American Tobacco (BAT) through the "Jupiter" strategic investment pool, Organigram enters the second half of the fiscal year with a massive $3.5 billion cash position to fuel further M&A and digital ecosystem integration.